Cargando…
Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report
INTRODUCTION: Mastocytosis is a rare disease consisting of a group of disorders characterized by a pathologic increase in the number of mast cells in one or more organ system. Treatment is symptomatic. Oral sodium cromoglicate (SCG) is the only treatment licensed for the treatment of mastocytosis. I...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904792/ https://www.ncbi.nlm.nih.gov/pubmed/20579383 http://dx.doi.org/10.1186/1752-1947-4-193 |
_version_ | 1782183913393750016 |
---|---|
author | Edwards, Alan M Hagberg, Hans |
author_facet | Edwards, Alan M Hagberg, Hans |
author_sort | Edwards, Alan M |
collection | PubMed |
description | INTRODUCTION: Mastocytosis is a rare disease consisting of a group of disorders characterized by a pathologic increase in the number of mast cells in one or more organ system. Treatment is symptomatic. Oral sodium cromoglicate (SCG) is the only treatment licensed for the treatment of mastocytosis. In this case we report how in a mastocytosis patient being treated with H(1 )and H(2 )antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement. This is the first report of this use of the drug in this disease. CASE PRESENTATION: The subject is a Caucasian woman aged 40 years. Symptoms of mastocytosis began when she was aged 13 years, but the diagnosis was not made until after her first pregnancy aged 33 years. Symptoms improved with H(1 )and H(2 )antihistamines, and oral sodium cromoglicate, but it required the addition of inhaled sodium cromoglicate to produce further improvement, specifically in the symptoms of bone pain, fatigue and headache. Doses of oral sodium cromoglicate had to be increased if challenged with a food to which the subject was sensitive. Doses of inhaled sodium cromoglicate had to be increased during the menstrual period. CONCLUSIONS: Patients suffering from the rare disease of mastocytosis have symptoms affecting many body systems. Symptoms result from the release of inflammatory mediators from mast cells. Sodium cromoglicate, a drug that reduces the release of mediators from mast cells, is effective in controlling gastrointestinal symptoms, but less effective in those affecting other body systems. In this case report we have shown that the addition of inhaled sodium cromoglicate controls the symptoms of bone pain, fatigue and headache and also that the doses have to be increased during the menstrual period. |
format | Text |
id | pubmed-2904792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29047922010-07-16 Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report Edwards, Alan M Hagberg, Hans J Med Case Reports Case Report INTRODUCTION: Mastocytosis is a rare disease consisting of a group of disorders characterized by a pathologic increase in the number of mast cells in one or more organ system. Treatment is symptomatic. Oral sodium cromoglicate (SCG) is the only treatment licensed for the treatment of mastocytosis. In this case we report how in a mastocytosis patient being treated with H(1 )and H(2 )antihistamines, and oral sodium cromoglicate, the addition of inhaled sodium cromoglicate resulted in further improvement. This is the first report of this use of the drug in this disease. CASE PRESENTATION: The subject is a Caucasian woman aged 40 years. Symptoms of mastocytosis began when she was aged 13 years, but the diagnosis was not made until after her first pregnancy aged 33 years. Symptoms improved with H(1 )and H(2 )antihistamines, and oral sodium cromoglicate, but it required the addition of inhaled sodium cromoglicate to produce further improvement, specifically in the symptoms of bone pain, fatigue and headache. Doses of oral sodium cromoglicate had to be increased if challenged with a food to which the subject was sensitive. Doses of inhaled sodium cromoglicate had to be increased during the menstrual period. CONCLUSIONS: Patients suffering from the rare disease of mastocytosis have symptoms affecting many body systems. Symptoms result from the release of inflammatory mediators from mast cells. Sodium cromoglicate, a drug that reduces the release of mediators from mast cells, is effective in controlling gastrointestinal symptoms, but less effective in those affecting other body systems. In this case report we have shown that the addition of inhaled sodium cromoglicate controls the symptoms of bone pain, fatigue and headache and also that the doses have to be increased during the menstrual period. BioMed Central 2010-06-26 /pmc/articles/PMC2904792/ /pubmed/20579383 http://dx.doi.org/10.1186/1752-1947-4-193 Text en Copyright ©2010 Edwards and Hagberg; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Edwards, Alan M Hagberg, Hans Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report |
title | Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report |
title_full | Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report |
title_fullStr | Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report |
title_full_unstemmed | Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report |
title_short | Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report |
title_sort | oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904792/ https://www.ncbi.nlm.nih.gov/pubmed/20579383 http://dx.doi.org/10.1186/1752-1947-4-193 |
work_keys_str_mv | AT edwardsalanm oralandinhaledsodiumcromoglicateinthemanagementofsystemicmastocytosisacasereport AT hagberghans oralandinhaledsodiumcromoglicateinthemanagementofsystemicmastocytosisacasereport |